Search Results

Andrew Tobin draws from his experience leading translational GPCR programs and co-founding Keltic Pharma As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel

Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria.

The vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics Ltd , a biotechnology company co-founded by Andrew with series A funding from the European

into industry, and his role leading and shaping multidisciplinary teams for screening and innovative therapeutics How advanced assay design is essential for translating cell-based GPCR signals to therapeutic outcomes Martin Marro leads the Cell Pharmacology group in the Diabetes, Obesity and Complications Therapeutic Marro’s career advanced through roles at Novartis and Tectonic Therapeutic, contributing to projects across key therapeutic areas—spanning metabolic, cardiovascular, and gastrointestinal diseases.

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

GPCR was created to break down barriers across academia, biotech, pharma, and CROs—so knowledge, tools including: Academic researchers (PI, postdoc, student) Industry scientists and R&D leaders Biotech and pharma

Your Team with Terry Kenakin’s Pharmacology Frameworks Used by discovery scientists across biotech, pharma Corner lessons and analysis • Ability to suggest topics relevant to your programs • Access for biotech, pharma

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics expertise and provides you with product solutions including cell-based assays for basic research through therapeutic industry-standard assays, designed for regulatory submissions, are backed by partnerships with leading pharma Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Explore GLP-1 Product Solutions to Support Obesity/Diabetes See GLP-1 Solutions Accelerating Obesity Therapeutics

development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic potency testing, and backed by thousands of peer-reviewed publications and partnerships with leading pharma opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic

and Group leader in Aventis, now Sanofi, Frankfurt, Germany - Head of in vitro Pharmacology at 7TM Pharma

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications For researchers working in biotech, pharma, or academia, this type of continuing education can strengthen

GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well

work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools for pharma Biology: The Role of Fluorescent Ligands in GPCR Research GPCRs are one of the most important families of therapeutic Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

creation of Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma

Prior to his role at Addgene, Jason held roles in academia, big pharma, and non-profit research organizations

Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity Development department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma HTRF technology and accelerate the company’s reagents use in academic labs, biotech companies, and pharma

thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares Therapeutics She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through 15:29 Unexpected allosteric pockets and the next wave of GPCR drug design 18:47 Which GPCR families pharma As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Showcase your specialized GPCR expertise to stand out from competitors and attract high-value biotech and pharma Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed

Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. The goal is to test therapeutic strategies targeting the AT1R, alpha-adrenergic, and beta-adrenergic iPSC-derived models, and patient-specific cells 18:44 Industry partnerships and the path from bench to pharma

a driver of drug action AI combined with functional, not only structural, data The academic-to-Big-Pharma-to-biotech Waldhoer, CSO of InterAx Biotech 02:19 — From zoology to GPCRs: fate, not choice 06:48 — Academia to Big Pharma

Unconventional GPCR Ligands <p class="font_8">Watch Now</p> Terry Kenakin The New Frontier of GPCR Therapeutics Sam Hoare Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies

He joined Mount Sinai through FlexMed — bypassing the MCAT — and was torn between a career in pharma analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic

Biotech – The unexpected journey into biotech entrepreneurship, providing GPCR profiling services to pharma

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

evolution of antibody engineering, with leadership roles at DIAX, Oncomed, Sutro Biopharma, and Lake Pharma record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

validation as prerequisites for meaningful GPCR pharmacology Career navigation across academia, big pharma to produce a distinct complex - different ligand selectivity, different signaling profile, different therapeutic

He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.